Treatment and outcomes of aortic endograft infection  by Smeds, Matthew R. et al.
From the Society for Vascular SurgeryFrom
R
th
m
A
la
vi
C
Auth
Pres
Su
Corr
52
The
to
m
0741
Cop
E
http
332Treatment and outcomes of aortic endograft
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Peter F. Lawrence, MD,d Sean Lyden, MD,e Javariah Fatima, MD,f andMark K. Eskandari, MD,g on behalf
of the Vascular Low-Frequency Disease Consortium, Little Rock, Ark; Rochester, Minn; Bradenton and
Gainesville, Fla; Los Angeles, Calif; Cleveland, Ohio; and Chicago, Ill
Objective: This study examined the medical and surgical management and outcomes of patients with aortic endograft
infection after abdominal endovascular aortic repair (EVAR) or thoracic endovascular aortic repair (TEVAR).
Methods: Patients diagnosed with infected aortic endografts after EVAR/TEVAR between January 1, 2004, and January
1, 2014, were reviewed using a standardized, multi-institutional database. Demographic, comorbidity, medical man-
agement, surgical, and outcomes data were included.
Results: An aortic endograft infection was diagnosed in 206 patients (EVAR, n [ 180; TEVAR, n [ 26) at a mean
22 months after implant. Clinical ﬁndings at presentation included pain (66%), fever/chills (66%), and aortic ﬁstula
(27%). Ultimately, 197 patients underwent surgical management after a mean of 153 days. In situ aortic replacement was
performed in 186 patients (90%) using cryopreserved allograft in 54, neoaortoiliac system in 21, prosthetic in 111 (83%
soaked in antibiotic), and 11 patients underwent axillary-(bi)femoral bypass. Graft cultures were primarily polymicrobial
(35%) and gram-positive (22%). Mean hospital length of stay was 23 days, with perioperative 30-day morbidity of 35%
and mortality of 11%. Of the nine patients managed only medically, four of ﬁve TEVAR patients died after mean of
56 days and two of four EVAR patients died; both deaths were graft-related (mean follow-up, 4 months). Nineteen
replacement grafts were explanted after a mean of 540 days and were most commonly associated with prosthetic graft
material not soaked in antibiotic and extra-anatomic bypass. Mean follow-up was 21 months, with life-table survival of
70%, 65%, 61%, 56%, and 51% at 1, 2, 3, 4, and 5 years, respectively.
Conclusions: Aortic endograft infection can be eradicated by excision and in situ or extra-anatomic replacement but is
often associated with early postoperative morbidity and mortality and occasionally with a need for late removal for
reinfection. Prosthetic graft replacement after explanation is associated with higher reinfection and graft-related com-
plications and decreased survival compared with autogenous reconstruction. (J Vasc Surg 2016;63:332-40.)With widespread use of aortic endograft placement for
treatment of aortic pathology, complications of endografts
are being increasingly reported. Infection of an endograft
placed during abdominal endovascular aortic repair
(EVAR) or thoracic endovascular aortic repair (TEVAR)
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://dx.doi.org/10.1016/j.jvs.2015.08.113complications and is reported to be rare, with an incidence
in small series of 0.2% to 5%1-9; however, there are
currently no large multi-institutional studies.
Although complete removal of the infected endograft is
the optimal approach for aortic graft infection treatment,10,11
in many cases EVAR or TEVAR are used in patients who are
unﬁt for open procedures, and therefore, the decision to
perform an explantation with thoracic aorta or pararenal
aortic cross-clamping is associated with a high risk of opera-
tive complications or death, or both. In addition, because
of the low incidence of infection, diagnosis may be delayed,
resulting in sepsis and other systemic complications. Optimal
management of aortic endograft infection, whether medical
with antibiotic therapy or surgical, is unknown, as is the
optimal surgical reconstruction technique. This multi-
institutional study was conducted to deﬁne the morbidity
and mortality in patients with endograft infection and deter-
mine the optimal treatment strategies for this disease.
METHODS
Patients with EVAR or TEVAR infection who were
diagnosed between 2004 and 2014 were included. Patients
were identiﬁed using pre-existing investigator databases
in addition to the following procedural and diagnosis
Table I. Patient demographics, comorbidities, and initial
endovascular aortic repair (EVAR) and thoracic
endovascular aortic repair (TEVAR) grafts
Variable
No. (%) or mean 6 SD
(N ¼ 206)
Sex
Male 161 (78)
Female 45 (22)
Age at diagnosis, years 68 6 9
Comorbidities
Hypertension 174 (84)
Smoking 119 (58)
Renal insufﬁciency 62 (30)
Diabetes mellitus 54 (26)
Congestive heart failure 45 (22)
Peripheral arterial disease 33 (16)
Chronic infection 31 (15)
Initial grafta
EVAR (n ¼ 180)
Cook Zenith 42 (23)
Gore Excluder 35 (19)
Medtronic AneuRx 23 (13)
Gore TAG 20 (11)
Medtronic Endurant 12 (7)
Endologix 8 (4)
Medtronic (unknown type) 7 (4)
Guidant Ancure 5 (3)
Medtronic Talent 4 (2)
Gore Viabahn 2 (1)
Unknown 22 (12)
TEVAR (n ¼ 26)
Gore TAG 14 (54)
Medtronic Talent 5 (19)
Cook Zenith 3 (11)
Bolton Relay 2 (8)
Endologix 1 (4)
Unknown 1 (4)
SD, Standard deviation.
aBolton, Sunrise, Fla; Cook, Bloomington, Ind; Endologix, Irvine, Calif;
Guidant, Indianapolis, Ind; Medtronic, Minneapolis, Minn; W. L. Gore and
Assoc, Flagstaff, Ariz.
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cal Association, Chicago, Ill) code 35907 (excision of
infected abdominal endograft), and International Classiﬁ-
cation of Diseases, Ninth Revision codes 996.62 (infection
and inﬂammatory reaction due to other vascular device,
implant, or graft), 996.74 (other complications due to
other vascular device, implant, or graft), 998.59 (other
postoperative infection), and 996.52 (mechanical compli-
cation due to other tissue graft, not classiﬁed elsewhere).
Primary study end points included morbidity and mo-
rality of surgical and nonsurgical treatment, and patient
survival. Secondary end points included freedom from
persistent sepsis, recurrent infection, graft explant, and
limb loss.
Vascular Low-Frequency Disease Consortium and
database management. The Vascular Low-Frequency
Disease Consortium is a multi-institutional program that
aims to improve the clinical care of patients with low-
frequency or uncommon vascular diseases where only
small series or discrepancies in management recommen-
dations exist within the published literature.
Obtaining Investigational Review Board (IRB)
approval was the responsibility of the principal investigator
at each institution. Patient consent was waived by all IRBs
due to the minimal risk and retrospective nature of the
study. After IRB approval, patients were identiﬁed, and
data were collected, then deidentiﬁed and transmitted to
the Vascular Low-Frequency Disease Consortium at the
University of California, Los Angeles.
The submitted data were examined for accuracy and
completeness, with incomplete, inconsistent, or abnormal
entries veriﬁed by the patient’s institution using their
unique patient identiﬁers. The principal investigator from
each institution was responsible for the validity and
completeness of all data submitted. The data were stored
in a password-encrypted central database. All study investi-
gators reviewed the collective data before abstract submis-
sion, presentation, and manuscript submission.
Statistics. Data were collected and maintained in an
Excel 14 database (Microsoft Corp, Redmond,Wash). Statis-
tical analysis was performed with SPSS Statistics 21 software
(IBMCorp,Armonk,NY) andPrism6.0 software (GraphPad
Software, La Jolla, Calif). Continuous variables are presented
as mean6 standard deviation unless noted otherwise. Differ-
ences between subgroups were analyzed using independent
Student t-test, Kruskal-Wallis test, Mann-Whitney U test,
and analysis of variance test. Unless numeric values are given,
percentages are not inclusive. Differences between subgroups
of noncontinuous variables were analyzed using the c2 test or
the Fisher exact test. Multivariable analysis was performed
using binary and multinomial logistic regression models.
Time-dependent variables were analyzed using Kaplan-Meier
life tables. For all comparative tests and analysis, a value ofP<
.05 was considered signiﬁcant.
RESULTS
Patient demographics and comorbidities. A total of
206 patients (78% male) were treated for infected aorticstent grafts, 180 (87%) EVAR and 26 (13%) TEVAR, at
19 institutions (range, 1-27 patients per institution).
The mean age was 68 years (range, 35-88 years), and
the average body mass index was 26.6 kg/m2 (range,
17-43 kg/m2). Hypertension was the most common co-
morbidity, occurring in 174 patients (84%), with other
cardiovascular risk factors present in a signiﬁcant portion
(Table I). Diabetes mellitus was present in 54 patients
(26%), 15% of patients had a history of chronic infections,
and 4% had a history of immunosuppression.
Index aortic procedure: Technical factors and
possible sources of infection. Infected EVAR and
TEVAR stent grafts removed included multiple commer-
cial devices (Table I). The index procedure used femoral
cutdown access in 66% of patients, and 65% of the index
aortic procedures were performed at hospitals other than
the institutions that removed the infected endografts. An
infection complicated the initial aortic operation in 70
patients (34%). with the most common being urinary tract
infection (Table II), and the original operation was
Table II. Sources of possible endograft infection
Possible source of infection No. (%) (N ¼ 205)
Infection at index operation 70 (34)
Groin infection 14 (7)
Urinary tract infection 16 (8)
Other infection 40 (19)
Contaminated index operation 29 (14)
Endoleak at index operation 52 (25)
No intervention 23 (11)
With intervention 29 (14)
Interval procedure 69 (34)
Interval known infection 78 (38)
Table III. Symptoms and ﬁndings at diagnosis of aortic
endograft infection
Presenting symptom No. (%) (N ¼ 206)
Pain 137 (66)
Back 71 (52)
Abdominal 47 (34)
Groin 8 (6)
Chest 7 (5)
Flank 4 (3)
Fever/chills 137 (66)
Aortic ﬁstula 55 (27)
Endoleak 50 (24)
Rupture 23 (11)
Asymptomatic 10 (5)
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initially detected in 52 patients (25%), with 29 (56%) un-
dergoing subsequent intervention. Interval operative pro-
cedures for nonaortic-related pathology were performed in
69 patients (34%). Infections were documented in 78 pa-
tients (38%) between the time of stent graft placement and
the diagnosis of stent graft infection that included sinusitis,
infected hematoma, liver abscess, spine abscess, tooth ab-
scess, vertebral infection, Q-fever, and endocarditis.
Symptoms/presentation and diagnosis. Common
symptoms at presentation included pain in 137 patients
(66%) and fever/chills in 137 (66%; Table III). Endoleak
was present in 50 patients (24%), and an aortic ﬁstula was
identiﬁed in 55 (27%). Patients with infected TEVAR were
more likely to have a ﬁstula than those with an infected
EVAR (12 of 26 vs 43 of 180; P ¼ .02), with the most
common being aortoesophageal. Only 10 patients (5%)
were asymptomatic and identiﬁed incidentally.
The average time between the initial endograft place-
ment and the detection of infection was 22 months (range,
0.2-158 months; Fig 1), with thoracic stent grafts detected
earlier, at a mean of 18 months (range, 0.6-70 months),
and abdominal stent graft infections identiﬁed at 24 months
(range, 0.2-158 months; P ¼ .067). Imaging identiﬁed the
infection in 196 patients (95%), most commonly with
computed tomography (CT) scan, in which 167 patients
(81%) had ﬁndings of infection. In addition, 71 (34%)
had a positive indium 111 leukocyte scan and eight (4%)
had ﬁndings suggestive of aortic infection on magnetic
resonance imaging. Preoperative blood cultures were posi-
tive in 123 patients (63%).
Medical management. Medical management with
broad-spectrum antibiotics was undertaken initially in
most patients; however, 197 patients (96%) ultimately
underwent surgical explantation (Fig 2). Five patients
(19%) in the TEVAR group never underwent surgical
treatment, compared with only four patients (2%) in the
EVAR group (mean follow-up, 4 months). Four patients
(80%) in the TEVAR group died at a mean of 56 days after
endograft infection diagnosis, and two (50%) of the EVAR
group died of graft-related causes.
Surgical management. Stent graft infection was surgi-
cally managed in 197 patients (96%). Urgent or emergencysurgery was performed in 37 (19%); of whom, 18 (49%)
had rupture, 16 (43%) had endoleak, and 9 (24%) had
aortic ﬁstula. The mean time from diagnosis to procedure
was 18 days. The interval between diagnosis and deﬁnitive
repair in the remaining 169 patients was 153 days (range,
1-1012 days). Aortic replacement with a Dacron (DuPont,
Wilmington, Del) graft was performed in 75 patients
(38%), cryopreserved allograft in 54 (27%), polytetraﬂuoro-
ethylene graft in 36 (18%), femoropopliteal neoaortoiliac
system (NAIS) in 21 (11%), and extra-anatomic bypass in
11 (6%). Before implantation, 56 of the 75 Dacron
replacement grafts were soaked in antibiotics, but only ﬁve
of 36 polytetraﬂuoroethylene grafts received antibiotic
impregnation.
Supraceliac clamping was required in 61 patients
(35%), clamping above the superior mesenteric artery was
required in 15 patients (9%), a suprarenal clamp was
required in 59 (34%), and clamping above one renal artery
was required in 9 (5%). In only 33 patients (19%) was
infrarenal clamping performed. Seven of the TEVAR infec-
tion group (27%) required left heart bypass.
The mean operative time was longer for patients un-
dergoing NAIS (543 minutes; range, 415-744 minutes)
or cryopreserved allograft (502 minutes; range, 243-
1029 minutes) procedures than those undergoing extra-
anatomic (320 minutes; range, 201-465 minutes) or
prosthetic (359 minutes; range, 230-682 minutes) bypass
(Table IV). Mean blood loss was 4067 mL, with no statis-
tical difference between procedure types. At least one addi-
tional procedure was needed in 71 patients at time of
infected graft explant (Table V).
Intraoperative cultures identiﬁed gram-positive organ-
isms in 42 patients (22%), with Streptococcus the most
prevalent bacteria. Gram-negative organisms were found
in 25 patients (13%), with Escherichia coli and Prevotella
(bacteroides) the most common. Fungus was identiﬁed in
eight patients (5%). Cultures were polymicrobial in 66 pa-
tients (35%) and negative in 56 (30%). Intraoperatively,
perigraft abscess was present in 87 patients (44%), bioﬁlm
was present in 31 (16%), and graft-bowel erosion was
present in 27 (14%). Postoperative antibiotic therapy was
continued indeﬁnitely in 122 patients (62%), and the
Fig 1. Time from the initial endograft placement in endovascular aortic repair (EVAR) or thoracic endovascular aortic
repair (TEVAR) to the diagnosis of aortic endograft infection in (A) patients with gram-positive and gram-negative
infections and (B) those with polymicrobial, fungal, and negative culture infections.
Fig 2. Flow chart details the management of patients with aortic endograft infection. Abx, Antibiotic; EVAR,
endovascular aortic repair; NAIS, neoaortoiliac system; TEVAR, thoracic endovascular aortic repair.
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(range, 11-1825 days).
Perioperative complications occurred in 69 patients
(35%), the most common of which was persistent sepsis
in 27 (14%; Table VI). Outcomes were independent of
institution and volume. Variables that were predictive of
persistent sepsis included use of a prosthetic graft for aortic
replacement, polymicrobial infection, and groin infection
after the initial aortic procedure. The replacement graft
ruptured in ﬁve patients at 7, 13, 35, 39, and 95 days afterendograft excision, and all but one subsequently died. Four
patients had thrombosis or occlusion of their grafts, but
there was no perioperative limb loss. There was no predi-
lection for type of replacement graft in the graft rupture
or failure groups.
The 30-day perioperative mortality was 11%, and the
mean length of stay after the procedure was 23 days (range,
1-94 days), with no statistical difference between patients
with infected EVAR vs TEVAR graft removal. The mean
follow-up was 21 months (range, 1-149 months), with
Table VI. Postoperative complications in patients
managed surgically
Complication No. (%) (N ¼ 197)
Persistent sepsis 27 (14)
Recurrent infection 12 (6)
Perioperative 9 (5)
Long-term 3 (2)
Myocardial infarction 9 (5)
Pneumonia 8 (4)
Acute kidney injury 6 (3)
Stroke 5 (3)
Arrhythmia 5 (3)
Graft rupture 5 (3)
Perioperative 2 (<1)
Long-term 3 (2)
Ischemic colitis 4 (2)
Acute respiratory failure 4 (2)
Anastomotic hemorrhage 4 (2)
Perioperative 3 (2)
Long-term 1 (<1)
Graft thrombosis/occlusion 4 (2)
Perioperative 3 (2)
Long-term 1 (<1)
Urinary tract infection 3 (2)
Table IV. Operative data in patients undergoing surgical management of aortic endograft infection
Variablea Extra-anatomic bypass (n ¼ 11) Prosthetic (n ¼ 111) Cryoallograft (n ¼ 54) NAIS (n ¼ 21) P value
EBL, mL 3909 6 1539 4142 6 524 3588 6 374 4986 6 752 NS
Operative time, min 320 6 99 359 6 22 502 6 54 543 6 38 <.001
Perioperative mortality 2 (18) 14 (13) 4 (7) 2 (10) .103
Complications 7 (64) 40 (36) 14 (26) 7 (33) .046
EBL, Estimated blood loss; NAIS, neoaortoiliac system; NS, not signiﬁcant.
aContinuous data are shown as the mean 6 standard deviation and categoric data as number (%).
Table V. Additional procedures performed during
infected aortic endograft explant
Procedure No. (%) (N ¼ 197)
Ureteral stenting 9 (5)
Vertebral body débridement 8 (4)
Aortoduodenal ﬁstula repair 6 (3)
Splenectomy 6 (3)
Esophagus repair 4 (2)
Duodenum repair 4 (2)
Small bowel repair 4 (2)
Omentoplasty 4 (2)
Retroperitoneal abscess drainage 4 (2)
Fasciotomy 4 (2)
Bovine pericardium patch angioplasty 3 (2)
Aortoenteric ﬁstula repair 2 (1)
Cholecystectomy 2 (1)
Colostomy 2 (1)
Renal bypass 2 (1)
Nephrectomy 2 (1)
Groin ﬂap coverage 2 (1)
Thrombectomy 2 (1)
Renal endarterectomy 1 (<1)
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placed for open reconstruction was necessary in 19 patients
at a postoperative mean of 540 days (range, 36-1253 days),
with life-table explantation rates of 6%, 13%, and 16% at 1,
3, and 5 years, respectively. Factors that were predictors of
replacement graft explantation on multivariate analysis
included procedure duration >540 minutes and use of an
extra-anatomic bypass.
Survival was worse in patients with gram-negative in-
fections than in those with gram-positive infections (56%
vs 31% survival at 5 years; P ¼ .011), and there was a trend
for decreased survival with polymicrobial infections,
although this was not statistically signiﬁcant. Patients
with abdominal stent graft infections had better survival
than those with thoracic stent graft infection (52% vs 29%
survival at 5 years; P ¼ .038), with most of the additional
deaths occurring during the perioperative period (Fig 3).
Survival was signiﬁcantly different when autogenous
reconstructions were compared with prosthetic reconstruc-
tions, with NAIS (65%) and cryopreserved (72%) in-line
reconstruction together having overall 5-year survival of
71% compared with 53% in patients with antibiotic-
soaked prosthetic and 12% in those treated with bare pros-
thetic grafts.Univariate analysis identiﬁed several factors associated
with graft and all-cause mortality (Table VII). Multivariate
predictors of all-cause mortality included uncontrolled hy-
pertension, renal insufﬁciency, chronic infection, endoleak
with no intervention, procedure duration >540 minutes,
blood loss >8000 mL, aortic ﬁstula, and polymicrobial
infection.
DISCUSSION
Fortunately, infection after EVAR or TEVAR is a
rare problem. Previous publications, consisting of small
single-center studies with only a small number of
patients,2-4,6,9,12-14 show that the overall incidence of
infection after endograft placement is estimated to occur
in <1% of cases. Our series represents a multicenter expe-
rience during a 10-year period and therefore cannot pro-
vide data on the incidence of endograft infection, because
more patients were referred to treatment centers from
other institutions, but our study provides an analysis of
a large number of patients managed for infected EVAR
or TEVAR. The differences between performing a
standardized review over a meta-analysis are that there
Fig 3. Patient survival (A) overall, (B) infected endovascular aortic repair (EVAR) vs thoracic endovascular aortic
repair (TEVAR), (C) gram-positive infections vs gram-negative infections, (D) polymicrobial infections vs gram-
positive, gram-negative, and fungal infections, (E) in-line reconstruction vs extra-anatomic bypass, and (F) autoge-
nous reconstruction vs prosthetic grafts soaked in antibiotics (Abx, in-line and bypass) vs prosthetic grafts not soaked in
antibiotics (in-line and bypass).
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to contribute varying numbers of patients to create a
robust database from which stronger conclusions can be
gleaned.
Explantation of endovascular stent grafts for any etiol-
ogy is associated with a high morbidity and mortality and
often requires a more proximal aortic clamp than the index
procedure would have required. Patients who require
explantation because of infection have worse outcomes
than those with endoleak or stent failure because of under-
lying sepsis, comorbidities, and the extent of resection
required.12
Diagnosis of infection occurred in the most of these
patients <22 months from the index operation, indicatingthat infection of the graft may occur relatively soon after
implantation. In fact, nearly 34% of the patients in our se-
ries had an infectious complication in the perioperative
period of their original operation, and the index procedure
in 14% was contaminated. These observations are sup-
ported by studies that show decreased resistance to infec-
tion within the ﬁrst week after implantation of covered
stents in a canine model.15
The mean of 156 days between diagnosis and treat-
ment in our study could be explained by an attempt by sur-
geons to avoid a second large abdominal operation and to
treat the patient medically, and most patients were started
on antibiotic therapy and medically optimized during this
period. There was also occasionally a delay in the patient’s
Table VII. Multivariate predictors associated with
morbidity and mortality in patients managed surgically
Graft-related mortality P value
Prosthetic graft (in-line and extra-anatomic) <.01
Estimated blood loss >6000 mL <.01
Chronic infection <.01
Procedure duration >420 minutes .018
Rupture at presentation .022
Preoperative creatinine >2.1 mg/dL .029
Society for Vascular Surgery comorbidity score >6 .042
Endoleak at presentation .043
Aortic ﬁstula at presentationa .084
Prosthetic graft not soaked in antibiotica .153
Groin infection complicationa .276
Age >70 yearsa .441
Infection between index procedure and endograft
infection diagnosisa
.687
Persistent sepsis
Prosthetic graft (in-line and extra-anatomic) .011
Polymicrobial infection .021
Groin infection after initial aortic procedure .042
Extra-anatomic bypass .045
Aortic ﬁstula at presentationa .117
Prosthetic graft not soaked in antibiotica .174
Gram-negative culturesa .335
Smoking historya .388
aIndicates the variable was signiﬁcant in univariate analysis.
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that managed the infected aorta.
Although placement of endografts in infected ﬁelds has
been reported, it may be appropriate to only use the
endograft as a bridge to open revascularization, because
these bridge grafts are prone to ongoing infection.16,17
In addition to the perioperative infectious complications
in our series, 38% of patients had an interval infection,
34% had an interval procedure that may have been a nidus
for infection, and 25% had an endoleak after the initial graft
placement that was treated with sac intervention in more
than half (most commonly for type II endoleaks). The
Zenith (Cook, Bloomington, Ind) EVAR device and the
TAG (W. L. Gore and Assoc, Flagstaff, Ariz) TEVAR de-
vice were the most common grafts removed, but this is
likely related to the prevalent use of these grafts rather
than a particular device predilection for infection. Given
these ﬁndings, clinicians should prescribe prophylactic anti-
biotic therapy in every EVAR/TEVAR patient, initially and
when undergoing subsequent invasive procedures, to
decrease possible contamination of the covered stents.
Our patients had a morbidity rate of w35% and an
overall mortality at 5 years of 51%. Those with TEVAR
had worse outcomes than EVAR in our series as well as
in others,13 with an overall 5-year mortality of 29%. This
increase in TEVAR mortality was predominantly in the
perioperative period and likely related to higher rates of
aortic ﬁstulization, need for left heart bypass, and a higher
cross-clamping level than in patients undergoing EVAR
excision. In addition, techniques that can be used readily
in the abdominal aorta, such as NAIS or extra-anatomic
bypass, are fraught with technical issues in the chest, thuslimiting the repair options in most cases to cryopreserved
allograft or prosthetic bypass with soft tissue coverage.
The standard of care for management of both EVAR
and TEVAR infection is explantation of the graft, débride-
ment of necrotic tissue, and reconstruction of the aorta,
often with autologous tissue coverage using omentum or
fascia lata. Interestingly, our data show a difference in out-
comes depending on the type of repair used. Patients with
prosthetic repairs, particularly if not impregnated with anti-
biotics, had worse survival than those with autogenous re-
pairs using cryopreserved venous or arterial bypasses or
deep vein harvested from the femoral-popliteal distribution
(NAIS procedure), despite these procedures taking longer.
In fact, on multivariate analysis, use of a prosthetic graft
was a predictor of overall graft-related mortality. Impreg-
nating the prosthetic grafts with rifampin improved out-
comes, and should be done if replacement with
autogenous tissue is not possible. Owing to the positive
binding mechanism between rifampin and Dacron, reinfec-
tion rates in the face of infection decrease to between 4%
and 22% when soaked with this antibiotic.18
Previous studies of open aortic graft infections found
the presence of an abscess was a contraindication to the
use of an in situ prosthetic aortic replacement.10,11 It is
possible that in the setting of infected EVAR/TEVAR,
the presence of an aneurysm sac behaves similarly to an ab-
scess, making prosthetic replacement less favorable than an
autologous or cryopreserved allograft. In addition, the acu-
ity of the operation may have inﬂuenced the type of repair.
It is possible that surgeons chose a prosthetic graft or pros-
thetic extra-anatomical bypass for emergency cases when
an NAIS procedure was not appropriate or when autoge-
nous grafts, such as cryopreserved aortoiliac grafts, were
not immediately available. Therefore, the degree of emer-
gency and conduit may have had an effect on the outcomes
associated with each procedure. Although the data did not
speciﬁcally support omental or soft tissue graft coverage,
omental or tissue coverage is recommended based on
extrapolation of data from open infected graft series.10
The better option for repair in our series was use of cry-
opreserved allograft or the femoral-popliteal vein (NAIS)
for aortic reconstruction. The NAIS procedure has been
established as an option in the management of infected
aortic grafts, with a low amputation rate, high long-term
patency, and acceptable perioperative and long-term mor-
tality.19 Its use in the management of infected stent grafts,
however, has not been well described. The main disadvan-
tage of the technique is the length of the operation, which
often requires two surgical teams, and venous morbidity,
which occurs as chronic venous insufﬁciency in up to
15% of patients, as well as a need for fasciotomies after
aortic reconstruction in up to 12% of patients.20 This was
not demonstrated in our data; nonetheless, because opera-
tive time was a predictor for graft-related mortality, the use
of NAIS should be reserved for patients who are able to
tolerate long operative times.
Use of cryopreserved allograft is another option for
aortic reconstruction in infected ﬁelds, with a 30-day
JOURNAL OF VASCULAR SURGERY
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reinfection rates at 5 years.21,22 Although the mean opera-
tive time for using cryopreserved allograft was 502 minutes,
the median was 418 minutes, and this time often included
performing additional procedures and, in some cases, thaw-
ing time or extending the graft to the distal common or su-
perﬁcial femoral artery using cryopreserved femoral artery.
Complications attributed to this procedure in the literature
include aneurysmal degeneration of the graft and bypass
limb thrombosis, neither of which was demonstrated in
our data.
Other predictors of all-cause and graft-related mortality
are similar to other large series of open abdominal opera-
tions and include the presence of chronic infection, long
duration of procedure, signiﬁcant blood loss, and renal
insufﬁciency. Polymicrobial infections predicted all-cause
mortality and persistent sepsis, so patients with polymicro-
bial cultures should be treated with long-term antibiotic
therapy in addition to complete explantation and
débridement.
Nearly all of the patients in this series were initially
started on broad-spectrum antibiotics before the deﬁnitive
operation, but only a small subset of our patients under-
went medical management alone. The follow-up period
in these patients was short, and the mortality rate was
high: nearly 80% of the medically managed TEVAR pa-
tients and 50% of the EVAR patients died during follow-
up. Although this study does not have the power to
compare medically managed patients with surgically
managed patients, it adds to the literature in supporting
surgical over medical management of infected stent grafts.
Limitations to this study arise mostly from the retro-
spective nature of the design, which is inevitable in a
low-frequency disease. In addition, the initial operations
in most of these patients were done at different institutions
other than at the treating centers, which made it difﬁcult to
determine the incidence of endograft infection. A compar-
ison with a noninfected EVAR/TEVAR group was not
made, so that risk factors for development of infection
could only be inferred. Finally, the rarity of this endograft
complication resulted in only small numbers of patients be-
ing treated by each contributing center, each with a
different experience and skill set. Thus, patients were not
standardized, even if receiving the same deﬁnitive
operation.
CONCLUSIONS
The diagnosis of infected endograft should be pursued
in symptomatic EVAR or TEVAR patients presenting with
history of chronic infection, interval procedures, infection
complicating the initial aortic repair, or a contaminated in-
dex case. Management should be surgical, with autogenous
reconstruction, and if this is not an option, prosthetic graft
impregnated with antibiotics should be used.
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Submitted Jul 8, 2015; accepted Aug 27, 2015.DISCUSSIONDr Jon Matsumura (Madison, Wisc). A great presentation,
Dr Duncan, on a really difﬁcult problem. My question is in regards
to the patients who had an interval procedure prior to their diag-
nosis of infection. What is the time between the interval procedure
and the infection? How many were translumbar embolizations? I
am concerned that if we are aggressive with treatment of type II
endoleaks, we might be subjecting those patients to an increased
risk of graft infection.
Dr Audra A. Duncan. Only 14% of the original endografts
had interval procedures for endoleak. I actually thought it was a
relatively low number. Not all the endoleaks were treated, slightly
more than half. We did not ask speciﬁcally about translumbar
approach in the data collection. I was suspecting the rate of endog-
raft interventions would be higher.
Dr William Jordan (Birmingham, Ala). Thank you,
Dr Duncan, for that presentation. It is very helpful information.
A question similar to Jon’s earlier one is, I would be interested
to know how many of these infections might have occurred rela-
tive to a nonvascular procedure. I feel that we have seen cases of
potentially lumbar spine operation or maybe even a urologic
intervention that then potentially seeds the graft. And I alsowonder if you can give us a recommendation on prophylactic an-
tibiotics for nonvascular procedures on patients who have had
endografts.
Dr Duncan. As you will see in the paper, we have a list of
“other procedures” that they underwent between endovascular
aortic repair and infection. The main ones we looked at were groin
infections and urinary tract infection (UTI), but there is a laundry
list of other procedures that they had.
At our institution we have patients take an antibiotic for any
invasive procedure, dental procedures, etc. It is not consistent
across institutions. I am not sure that we have data to support mak-
ing that recommendation, but it is certainly something that we do
as a practice.
Dr Anil Hingorani (Brooklyn, NY). Excellent set of data. I
had a question about the cryopreserved procedures. Why do
they take so long? I thought usually the neoaortoiliac system
(NAIS) would take longer.
Dr Duncan. I don’t know. There is some preparation time
required with thawing the graft, etc, and preparing it. Sometimes
it leaks from the lumbar sites. That was an unexpected number,
I’ll admit.
